The Immune Response Announces New Phase II NeuroVax Study

The Immune Response, a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), has announced a new Phase II study to investigate the long-term safety, mechanism-of-action, and utility of a quarterly dosing regimen of NeuroVax, an investigational T-cell receptor peptide vaccine for multiple sclerosis.

NeuroVax is an immune-based therapy designed to specifically down-regulate the body's destructive immune responses observed in MS patients to alleviate the impact of the disease.